Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Paul Feuerstadt, Thomas Louie et al.|Drugs|2022Cited by 273
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Paul Feuerstadt, Maha Assi et al.|Drugs|2022Cited by 6